Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Juli 2024 - 1:30PM
Business Wire
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company
committed to advancing new medicines for patients with cancer,
today announced the grant of stock options to purchase 108,292
shares of its common stock to seven new employees. The awards were
granted pursuant to the Nasdaq inducement grant exception as an
inducement material to the employees’ acceptance of employment with
Verastem Oncology in accordance with Nasdaq Listing Rule
5635(c)(4). The stock options have an exercise price equal to $3.25
per share, the closing price of Verastem Oncology’s common stock as
reported by Nasdaq on July 1, 2024. The stock options to purchase
78,292 shares of common stock that were granted to seven new
employees will vest at a rate of twenty-five percent (25%) on the
one-year anniversary of each employee’s date of hire, with the
remaining shares vesting quarterly over the next three (3) years in
equal quarterly amounts, provided the employee continues to serve
as an employee of or other service provider to Verastem Oncology on
each such vesting date. A stock option to purchase 30,000 shares of
common stock granted to one new employee will vest upon the
achievement of certain regulatory milestones, provided that the
employee continues to serve as an employee of or other service
provider to Verastem Oncology on each such vesting date.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a
late-stage development biopharmaceutical company committed to the
development and commercialization of new medicines to improve the
lives of patients diagnosed with cancer. Our pipeline is focused on
RAS/MAPK-driven cancers, specifically novel small molecule drugs
that inhibit critical signaling pathways in cancer that promote
cancer cell survival and tumor growth, including RAF/MEK inhibition
and FAK inhibition. For more information, please visit
www.verastem.com and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708142554/en/
For Investor and Media Inquiries: Julissa Viana Vice
President, Corporate Communications and Investor Relations
investors@verastem.com or media@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
Verastem (NASDAQ:VSTM)
Historical Stock Chart
Von Feb 2024 bis Feb 2025